DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the contract signing for a Phase IV, eight-year, 500-site, 5,000-patient study worth approximately $900,000 with a global specialty pharmaceutical and medication delivery company. This non-interventional, multi-center study will be deployed internationally utilizing DATATRAK eClinical™ for the observation of treatment of Renal Anemia.
"This client has previously invested in our Technology Transfer training and is now strategically positioned to realize the maximum efficiency and benefit from its DATATRAK ONE™ implementation," said Laurence Birch, DATATRAK's Chairman of the Board. "The selection of DATATRAK eClinical™ for this study attests to the robustness and reliability of the platform and underscores this client's long-term commitment to DATATRAK."
AI reveals key follicle sizes to boost IVF success